Others

LY2608204 is a potent used to treat type 2 diabetes. In a clinical trial, a study was performed to evaluate the safety and tolerability of LY2608204 in patients with type 2 diabetes.

Tirasemtiv amplifies skeletal muscle response to nerve activation in humans.

Bioymifi is a potent and selective small molecule agonist of DR5 that directly targets DR5, specifically binds the ECD of DR5 (Kd ~1.2 μM), and induces the formation of DR5 aggregates and DR5 activation.

Carglumic acid (N-Carbamyl-L-glutamic acid), a functional analogue of N-acetylglutamate (NAG) and a carbamoyl phosphate synthetase 1 (CPS1) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.

Benfluorex hydrochloride (JP-992 hydrochloride) is a hepatic nuclear factor 4 alpha (HNF4α) activator.

G6PD activator AG1 is a glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 ?μ, extracted from patent WO2019023264A1, compound AG1.